Gilead Sciences (GILD) Q2 FY25 earnings call

Gilead delivered a very strong second quarter, exceeding expectations with robust growth in its HIV portfolio, particularly Biktarvy and Descovy, and the successful early launch of Yeztugo for HIV prevention. Despite headwinds from lower Veklury sales and Medicare Part D redesign, the company raised its full-year revenue and EPS guidance. The quarter also saw significant clinical progress, including positive Phase III results for Trodelvy and advancements in the cell therapy pipeline, underscoring strong R&D and commercial execution.